OverviewLitigationPatentsTrademarksStatisticsNews

Company IP Overview

Recent StatisticsView All
Subscription-Only
View Concierge Program
TrademarksView All
Trademark Applications Filed Each Year
NewsView All
Pedram Sameni
•
Patexia Insight 192: Top Brand and Generic Companies in ANDA 2023
Pedram Sameni
•
Nov 9, 2023
In August, our much-anticipated fourth annual ANDA Litigation Intelligence Report made its entrance into the world of pharmaceutical litigation. This... Read More
Mikele Bicolli
•
Migraine Drug: Eli Lilly's Landmark Overturn Victory in Patent Battle
Mikele Bicolli
•
Sep 28, 2023
    In a groundbreaking legal development, Eli Lilly has secured a remarkable victory in a high-stakes patent battle that... Read More
Pedram Sameni
•
Patexia Insight 152: Best Performing Brand and Generic Pharmas of 2022 (ANDA)
Pedram Sameni
•
Sep 22, 2022
Last month, we released our third annual ANDA Litigation Intelligence Report evaluating all stakeholders in ANDA/Hatch-Waxman cases filed over the... Read More
Recent StatisticsView All
Subscription-Only
View Concierge Program
TrademarksView All
Trademark Applications Filed Each Year
NewsView All
Pedram Sameni
•
Patexia Insight 192: Top Brand and Generic Companies in ANDA 2023
Pedram Sameni
•
Nov 9, 2023
In August, our much-anticipated fourth annual ANDA Litigation Intelligence Report made its entrance into the world of pharmaceutical litigation. This... Read More
Mikele Bicolli
•
Migraine Drug: Eli Lilly's Landmark Overturn Victory in Patent Battle
Mikele Bicolli
•
Sep 28, 2023
    In a groundbreaking legal development, Eli Lilly has secured a remarkable victory in a high-stakes patent battle that... Read More
Pedram Sameni
•
Patexia Insight 152: Best Performing Brand and Generic Pharmas of 2022 (ANDA)
Pedram Sameni
•
Sep 22, 2022
Last month, we released our third annual ANDA Litigation Intelligence Report evaluating all stakeholders in ANDA/Hatch-Waxman cases filed over the... Read More